Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study

NCT07488572 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07488572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07488572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
November 1, 2025
Completion date
June 1, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal cell carcinoma, renal cell carcinoma (rcc)